Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Jonsson, Palmi V
Launer, Lenore J
Legido Quigley, Cristina
MetadataShow full item record
CitationBlood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. 2016, 12 (7):815-22 Alzheimers Dement
AbstractRecently, quantitative metabolomics identified a panel of 10 plasma lipids that were highly predictive of conversion to Alzheimer's disease (AD) in cognitively normal older individuals (n = 28, area under the curve [AUC] = 0.92, sensitivity/specificity of 90%/90%).
Quantitative targeted metabolomics in serum using an identical method as in the index study.
We failed to replicate these findings in a substantially larger study from two independent cohorts-the Baltimore Longitudinal Study of Aging ([BLSA], n = 93, AUC = 0.642, sensitivity/specificity of 51.6%/65.7%) and the Age, Gene/Environment Susceptibility-Reykjavik Study ([AGES-RS], n = 100, AUC = 0.395, sensitivity/specificity of 47.0%/36.0%). In analyses applying machine learning methods to all 187 metabolite concentrations assayed, we find a modest signal in the BLSA with distinct metabolites associated with the preclinical and symptomatic stages of AD, whereas the same methods gave poor classification accuracies in the AGES-RS samples.
We believe that ours is the largest blood biomarker study of preclinical AD to date. These findings underscore the importance of large-scale independent validation of index findings from biomarker studies with relatively small sample sizes.
DescriptionEfst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn
RightsArchived with thanks to Alzheimer's & dementia : the journal of the Alzheimer's Association
- Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
- Authors: Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, O'Brien R, Pletnikova O, Troncoso JC, Toledo J, Baillie R, Arnold M, Kastenmueller G, Nho K, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R, Legido-Quigley C, Thambisetty M
- Issue date: 2018 Jan
- Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease.
- Authors: Huan T, Tran T, Zheng J, Sapkota S, MacDonald SW, Camicioli R, Dixon RA, Li L
- Issue date: 2018
- Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging.
- Authors: Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, Tran J, Lazaropoulos MP, Chawla S, Gulyani S, Eitan E, An Y, Huang CW, Oh ES, Lyketsos CG, Resnick SM, Goetzl EJ, Ferrucci L
- Issue date: 2019 Nov 1
- Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.
- Authors: Davatzikos C, Xu F, An Y, Fan Y, Resnick SM
- Issue date: 2009 Aug
- Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis.
- Authors: Huo Z, Yu L, Yang J, Zhu Y, Bennett DA, Zhao J
- Issue date: 2020 Feb